Abstract:Sarcoidosis is a multi-system disease of unknown etiology characterized by the formation of granulomas in various organs. It affects people of all ethnic backgrounds and occurs at any time of life but is more frequent in African Americans and Scandinavians and in adults between 30 and 50 years of age. Sarcoidosis can affect any organ with a frequency varying according to ethnicity, sex and age. Intrathoracic involvement occurs in 90% of patients with symmetrical bilateral hilar adenopathy and/or diffuse lung micronodules, mainly along the lymphatic structures which are the most affected system. Among extrapulmonary manifestations, skin lesions, uveitis, liver or splenic involvement, peripheral and abdominal lymphadenopathy and peripheral arthritis are the most frequent with a prevalence of 25–50%. Finally, cardiac and neurological manifestations which can be the initial manifestation of sarcoidosis, as can be bilateral parotitis, nasosinusal or laryngeal signs, hypercalcemia and renal dysfunction, affect less than 10% of patients. The diagnosis is not standardized but is based on three major criteria: a compatible clinical and/or radiological presentation, the histological evidence of non-necrotizing granulomatous inflammation in one or more tissues and the exclusion of alternative causes of granulomatous disease. Certain clinical features are considered to be highly specific of the disease (e.g., Löfgren’s syndrome, lupus pernio, Heerfordt’s syndrome) and do not require histological confirmation. New diagnostic guidelines were recently published. Specific clinical criteria have been developed for the diagnosis of cardiac, neurological and ocular sarcoidosis. This article focuses on the clinical presentation and the common differentials that need to be considered when appropriate.

The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis

Recent advances in sarcoidosis

Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis

Delphi Consensus Recommendations for a Treatment Algorithm in Pulmonary Sarcoidosis

Sarcoidosis: A Review of the Guidelines and What's To Come

Clinical management of pulmonary sarcoidosis

Progress of Inhaled Corticosteroids in Treatment of Pulmonary Sarcoidosis

Progress of drug therapies for sarcoidosis

ERS clinical practice guidelines on treatment of sarcoidosis

Features of the current course and treatment of pulmonary sarcoidosis (case from clinical practice)

Five principles and protocols for the clinician based on the 2021 ERS and BTS statements for treating sarcoidosis

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

How to Use and Monitor Sarcoidosis Medications

Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis

High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities

Gastrointestinal Manifestations of Sarcoidosis: A State-of-the-Art, Comprehensive Review of the Literature—Practical Clinical Insights and Many Unmet Needs on Diagnosis and Treatment

Phenotypes and Serum Biomarkers in Sarcoidosis

BTS Clinical Statement on pulmonary sarcoidosis

Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments

[Cardiac sarcoidosis: a diagnostic and therapeutic challenge]

Treatment of cardiac sarcoidosis